Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval entities : Ultragenyx pharmaceutical inc. save search
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy
Published: 2021-09-09 (Crawled : 08:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -0.58%
H: 2.56%
C: -0.46%
media treatment approval
MEDIA ADVISORY: Ultragenyx Canada Announces Health Canada Approval of a Second Indication for Crysvita™ (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults
Published: 2021-09-07 (Crawled : 12:15) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 1.8%
H: 1.99%
C: -0.35%
canada approval media treatment injection approval
Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and ChildrenDojolvi is the only approved therapy for this rare, life-threatening metabolic disorder
Published: 2021-08-23 (Crawled : 13:00) - biospace.com/
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 4.68%
H: 4.22%
C: 4.04%
treatment brazil therapy metabolic children approval rare
Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children
Published: 2021-08-23 (Crawled : 13:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 4.68%
H: 4.22%
C: 4.04%
treatment brazil children approval
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Spain
Published: 2021-07-13 (Crawled : 08:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -0.16%
H: 2.26%
C: -4.01%
media treatment approval
GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome
Published: 2021-06-10 (Crawled : 13:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 0.2%
H: 8.89%
C: 5.07%
treatment approval syndros
Ultragenyx Announces Approval of Dojolvi™ (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children
Published: 2021-02-17 (Crawled : 14:01) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -0.67%
H: 1.05%
C: -0.19%
treatment approval children
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.